Last reviewed 2026-04-22 · How we verify

EGCG as putative neuroprotective agent

Dr. Johannes Levin · Phase 3 active Small molecule

EGCG as putative neuroprotective agent is a Natural polyphenol / antioxidant Small molecule drug developed by Dr. Johannes Levin. It is currently in Phase 3 development for Neuroprotection in neurodegenerative disease (specific indication not publicly detailed). Also known as: Sunphenon EGCg.

EGCG (epigallocatechin gallate) is a polyphenol from green tea that exerts neuroprotection through antioxidant and anti-inflammatory pathways, reducing neuronal damage and protein aggregation.

EGCG (epigallocatechin gallate) is a polyphenol from green tea that exerts neuroprotection through antioxidant and anti-inflammatory pathways, reducing neuronal damage and protein aggregation. Used for Neuroprotection in neurodegenerative disease (specific indication not publicly detailed).

Likelihood of approval

55.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	EGCG as putative neuroprotective agent
Also known as	Sunphenon EGCg
Sponsor	Dr. Johannes Levin
Drug class	Natural polyphenol / antioxidant
Modality	Small molecule
Therapeutic area	Neurology
Phase	Phase 3

Mechanism of action

EGCG is a catechin polyphenol that crosses the blood-brain barrier and scavenges reactive oxygen species while inhibiting pro-inflammatory signaling cascades implicated in neurodegeneration. It may also modulate protein misfolding and aggregation pathways relevant to neurodegenerative diseases, potentially stabilizing neuronal function and reducing cell death.

Approved indications

Neuroprotection in neurodegenerative disease (specific indication not publicly detailed)

Common side effects

Gastrointestinal upset
Hepatotoxicity (at high doses)

Key clinical trials

Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EGCG as putative neuroprotective agent CI brief — competitive landscape report
EGCG as putative neuroprotective agent updates RSS · CI watch RSS
Dr. Johannes Levin portfolio CI

Frequently asked questions about EGCG as putative neuroprotective agent

What is EGCG as putative neuroprotective agent?

EGCG as putative neuroprotective agent is a Natural polyphenol / antioxidant drug developed by Dr. Johannes Levin, indicated for Neuroprotection in neurodegenerative disease (specific indication not publicly detailed).

How does EGCG as putative neuroprotective agent work?

EGCG (epigallocatechin gallate) is a polyphenol from green tea that exerts neuroprotection through antioxidant and anti-inflammatory pathways, reducing neuronal damage and protein aggregation.

What is EGCG as putative neuroprotective agent used for?

EGCG as putative neuroprotective agent is indicated for Neuroprotection in neurodegenerative disease (specific indication not publicly detailed).

Who makes EGCG as putative neuroprotective agent?

EGCG as putative neuroprotective agent is developed by Dr. Johannes Levin (see full Dr. Johannes Levin pipeline at /company/dr-johannes-levin).

Is EGCG as putative neuroprotective agent also known as anything else?

EGCG as putative neuroprotective agent is also known as Sunphenon EGCg.

What drug class is EGCG as putative neuroprotective agent in?

EGCG as putative neuroprotective agent belongs to the Natural polyphenol / antioxidant class. See all Natural polyphenol / antioxidant drugs at /class/natural-polyphenol-antioxidant.

What development phase is EGCG as putative neuroprotective agent in?

EGCG as putative neuroprotective agent is in Phase 3.

What are the side effects of EGCG as putative neuroprotective agent?

Common side effects of EGCG as putative neuroprotective agent include Gastrointestinal upset, Hepatotoxicity (at high doses).

Drug class: All Natural polyphenol / antioxidant drugs
Manufacturer: Dr. Johannes Levin — full pipeline
Therapeutic area: All drugs in Neurology
Indication: Drugs for Neuroprotection in neurodegenerative disease (specific indication not publicly detailed)
Also known as: Sunphenon EGCg

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing